Trials / Completed
CompletedNCT05765578
An Observational Study of Moderna COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)
DisCOVEries 2 - An Observational Study to Evaluate the Immunogenicity of mRNA COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,713 (actual)
- Sponsor
- ModernaTX, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The goal of this observational study is to analyze binding antibody levels in adults in the United States (US) after receiving coronavirus disease 2019 (COVID-19) bivalent boosters (original and omicron BA.4/5) and updated COVID-19 vaccines (XBB.1.5).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Moderna COVID-19 Vaccine | Sterile liquid for injection. Intervention not administered through this study. |
| BIOLOGICAL | Moderna mRNA1273.222 Booster | Sterile liquid for injection. Intervention not administered through this study. |
| BIOLOGICAL | Pfizer COVID-19 Vaccine | Sterile liquid for injection. Intervention not administered through this study. |
| BIOLOGICAL | Moderna 2023 Updated COVID-19 vaccine (XBB.1.5) | Sterile liquid for injection. Intervention not administered through this study. |
| BIOLOGICAL | Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5) | Sterile liquid for injection. Intervention not administered through this study. |
Timeline
- Start date
- 2023-03-08
- Primary completion
- 2024-06-17
- Completion
- 2024-06-17
- First posted
- 2023-03-13
- Last updated
- 2024-07-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05765578. Inclusion in this directory is not an endorsement.